MTOR and neoplasm: Interestingly, previous studies suggested that targeting PI3K/AKT/mTOR signalling could inhibit tumour progression by augmenting tumour immunosurveillance, preventing activation of immunosuppressive signalling and activating anti-tumour immunity [42, 43].